Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jun 12;1(14):968-971.
doi: 10.1182/bloodadvances.2017007047. eCollection 2017 Jun 13.

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics

Thomas McKerrell  1   2   3 , Naomi Park  1 , Jianxiang Chi  4   5 , Grace Collord  1 , Thaidy Moreno  6 , Hannes Ponstingl  1 , Joao Dias  7 , Petroula Gerasimou  4   5 , Kiki Melanthiou  8 , Chrystalla Prokopiou  9 , Marios Antoniades  8 , Ignacio Varela  6 , Paul A Costeas  4   5 , George S Vassiliou  1   2   3   4
Affiliations

JAK2 V617F hematopoietic clones are present several years prior to MPN diagnosis and follow different expansion kinetics

Thomas McKerrell et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: G.S.V. is a consultant for KYMAB and receives an educational grant from Celgene. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Preclinical expansion of JAK2 V617F clones in 12 MPN patients. (A) Schema of blood sample collection from 12 individuals at the time of registration as stem cell donors at the Cyprus Bone Marrow Donor Registry and at the time they were diagnosed with MPN 4.6 to 15.2 years later. (B) Variant allele fraction (VAF) sizes of JAK2 V617F–positive clones at the 2 time points against the age of participants at the time. The specific diagnosis is indicated in brackets next to each patient’s ID, and the average annual rise in JAK2 V617F VAF is indicated in the upper right quadrant of each plot. Samples P3, P7, and P8 had no detectable JAK2 V617F at donor registration. The VAF rise for SRSF2 P95R in patient P3 is show in red.
See this image and copyright information in PMC

References

    1. Baxter EJ, Scott LM, Campbell PJ, et al. ; Cancer Genome Project. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005;365(9464):1054-1061. - PubMed
    1. Levine RL, Wadleigh M, Cools J, et al. . Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell. 2005;7(4):387-397. - PubMed
    1. Kralovics R, Passamonti F, Buser AS, et al. . A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med. 2005;352(17):1779-1790. - PubMed
    1. James C, Ugo V, Le Couédic JP, et al. . A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature. 2005;434(7037):1144-1148. - PubMed
    1. Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014(1):287-296. - PubMed